{"id":1655,"date":"2024-03-08T14:05:36","date_gmt":"2024-03-08T14:05:36","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1655"},"modified":"2024-03-08T14:05:38","modified_gmt":"2024-03-08T14:05:38","slug":"fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/","title":{"rendered":"FDA Delays Decision on Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Donanemab"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Eli Lilly&#8217;s anticipation for the Food and Drug Administration&#8217;s approval decision regarding its Alzheimer&#8217;s treatment, donanemab, faces a setback as the agency extends its review timeline. In a surprising move, the FDA intends to convene an impromptu meeting with external advisors to delve deeper into the drug&#8217;s safety and efficacy, prompting uncertainties around the approval date.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Initially slated for approval by the end of the first quarter, the FDA&#8217;s decision deadline was already postponed from its expected approval last year. Eli Lilly&#8217;s donanemab showed promising results in significantly slowing Alzheimer&#8217;s progression in late-stage trials, although concerns linger over safety issues like brain swelling and bleeding associated with similar drugs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The delay underscores the FDA&#8217;s cautious approach in evaluating Alzheimer&#8217;s treatments, given the condition&#8217;s pervasive impact and the urgent need for effective therapies. Eli Lilly remains optimistic about donanemab&#8217;s potential to offer substantial benefits to those with early symptomatic Alzheimer&#8217;s, despite the unexpected regulatory hurdle.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA&#8217;s forthcoming review will scrutinize an 18-month phase three trial involving over 1,700 patients in the early stages of Alzheimer&#8217;s, focusing on safety outcomes and the trial&#8217;s unique design. Eli Lilly&#8217;s commitment to working closely with the FDA and stakeholders underscores its dedication to navigating the regulatory process and addressing concerns surrounding donanemab&#8217;s development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/u-s-labor-market-resilience-shows-in-february-job-data\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">U.S. Labor Market Resilience Shows in February Job Data<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly&#8217;s anticipation for the Food and Drug Administration&#8217;s approval decision regarding its Alzheimer&#8217;s treatment, donanemab, faces a setback as the agency extends its review timeline. In a surprising move, the FDA intends to convene an impromptu meeting with external advisors to delve deeper into the drug&#8217;s safety and efficacy, prompting uncertainties around the approval [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1544,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[361,309],"tags":[],"coauthors":[453],"class_list":["post-1655","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-large-cap","category-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Delays Decision on Eli Lilly&#039;s Alzheimer&#039;s Drug, Donanemab - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Delays Decision on Eli Lilly&#039;s Alzheimer&#039;s Drug, Donanemab - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly&#8217;s anticipation for the Food and Drug Administration&#8217;s approval decision regarding its Alzheimer&#8217;s treatment, donanemab, faces a setback as the agency extends its review timeline. In a surprising move, the FDA intends to convene an impromptu meeting with external advisors to delve deeper into the drug&#8217;s safety and efficacy, prompting uncertainties around the approval [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-08T14:05:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-08T14:05:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-pixabay-53404-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1703\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"FDA Delays Decision on Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Donanemab\",\"datePublished\":\"2024-03-08T14:05:36+00:00\",\"dateModified\":\"2024-03-08T14:05:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/\"},\"wordCount\":251,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-pixabay-53404-scaled.jpg\",\"articleSection\":[\"Large-Cap\",\"Pharmaceuticals\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/\",\"name\":\"FDA Delays Decision on Eli Lilly's Alzheimer's Drug, Donanemab - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-pixabay-53404-scaled.jpg\",\"datePublished\":\"2024-03-08T14:05:36+00:00\",\"dateModified\":\"2024-03-08T14:05:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-pixabay-53404-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-pixabay-53404-scaled.jpg\",\"width\":2560,\"height\":1703},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/03\\\/08\\\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Delays Decision on Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Donanemab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Delays Decision on Eli Lilly's Alzheimer's Drug, Donanemab - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/","og_locale":"en_US","og_type":"article","og_title":"FDA Delays Decision on Eli Lilly's Alzheimer's Drug, Donanemab - Stoxpo","og_description":"Eli Lilly&#8217;s anticipation for the Food and Drug Administration&#8217;s approval decision regarding its Alzheimer&#8217;s treatment, donanemab, faces a setback as the agency extends its review timeline. In a surprising move, the FDA intends to convene an impromptu meeting with external advisors to delve deeper into the drug&#8217;s safety and efficacy, prompting uncertainties around the approval [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/","og_site_name":"Stoxpo","article_published_time":"2024-03-08T14:05:36+00:00","article_modified_time":"2024-03-08T14:05:38+00:00","og_image":[{"width":2560,"height":1703,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-pixabay-53404-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"FDA Delays Decision on Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Donanemab","datePublished":"2024-03-08T14:05:36+00:00","dateModified":"2024-03-08T14:05:38+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/"},"wordCount":251,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-pixabay-53404-scaled.jpg","articleSection":["Large-Cap","Pharmaceuticals"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/","name":"FDA Delays Decision on Eli Lilly's Alzheimer's Drug, Donanemab - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-pixabay-53404-scaled.jpg","datePublished":"2024-03-08T14:05:36+00:00","dateModified":"2024-03-08T14:05:38+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-pixabay-53404-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-pixabay-53404-scaled.jpg","width":2560,"height":1703},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/03\/08\/fda-delays-decision-on-eli-lillys-alzheimers-drug-donanemab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"FDA Delays Decision on Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Donanemab"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1655"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1655\/revisions"}],"predecessor-version":[{"id":1656,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1655\/revisions\/1656"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1544"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1655"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}